Artiva Biotherapeutics, Inc. (ARTV) AI Stock Price Forecast & Investment Analysis
Latest Analysis Date: August 22, 2025
Artiva Biotherapeutics, Inc. (ARTV) - Comprehensive Stock Analysis & Investment Research
Company Overview & Business Profile
Artiva Biotherapeutics, Inc. (Stock Symbol: ARTV)
is a leading company in the Life Sciences sector
, specifically operating within the Biological Products, (No Diagnostic Substances) industry.
.
The company has established itself as
an emerging investment opportunity with substantial growth potential.
Financial Performance & Key Metrics Analysis
Annual Revenue: $30 million
generating a -117.1% net profit margin
.
Market Capitalization: $70 million - Classified as a
small-cap investment offering high growth potential.
Advanced AI Stock Prediction & Price Target Analysis
🚀 Unlock Premium AI Predictions to access our advanced machine learning forecasts for Artiva Biotherapeutics, Inc. stock, including 7-day, 30-day, and 90-day price targets with confidence intervals and risk assessments.
Market Position & Competitive Advantage Analysis
Artiva Biotherapeutics, Inc. strategically competes in the highly dynamic
Biological Products, (No Diagnostic Substances) marketplace,
representing an emerging small-cap investment with substantial growth potential and market disruption capabilities
.
.
Artiva Biotherapeutics, Inc. Stock Price Chart and Technical Analysis
Loading chart data...
Loading Artiva Biotherapeutics, Inc. interactive price chart and technical analysis...
Deep dive into Artiva Biotherapeutics, Inc.'s financial health, valuation metrics, and operational efficiency to make informed investment decisions.
Understanding Valuation Metrics
What these metrics mean: Valuation metrics help determine if Artiva Biotherapeutics, Inc. stock is fairly priced compared to its earnings, assets, and market position.
How to read them: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.
For Artiva Biotherapeutics, Inc.:
P/B Ratio0.47x
Market Cap$70M
EPS$-3.09
Book Value/Share$6.11
Understanding Profitability Metrics
What these metrics mean: These ratios measure how efficiently Artiva Biotherapeutics, Inc. converts revenue into profit and generates returns for shareholders.
How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.
For Artiva Biotherapeutics, Inc.:
Operating Margin-114.5%
Net Margin-117.1%
Understanding Financial Health Metrics
What these metrics mean: These ratios assess Artiva Biotherapeutics, Inc.'s ability to meet short-term obligations and manage debt levels effectively.
How to read them: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.
For Artiva Biotherapeutics, Inc.:
Understanding Cash Flow Metrics
What these metrics mean: Cash flow metrics reveal Artiva Biotherapeutics, Inc.'s ability to generate cash from operations and fund growth initiatives.
How to read them: Positive operating cash flow is crucial. Free cash flow shows money available for dividends, buybacks, or investments.
For Artiva Biotherapeutics, Inc.:
Understanding Operational Efficiency Metrics
What these metrics mean: These ratios measure how effectively Artiva Biotherapeutics, Inc. uses its assets and manages working capital.
How to read them: Higher turnover ratios indicate efficient asset utilization. Shorter collection periods show effective credit management.
For Artiva Biotherapeutics, Inc.:
Understanding Financial Statement Data
What these metrics mean: Key figures from Artiva Biotherapeutics, Inc.'s income statement and balance sheet showing absolute financial performance.
How to read them: Revenue shows business scale, while margins indicate profitability. Balance sheet items reveal financial structure.
For Artiva Biotherapeutics, Inc.: With annual revenue of $30M, Artiva Biotherapeutics, Inc. represents a smaller but potentially high-growth operation.
Income Statement ($ Millions)
Total Revenue$30M
R&D Expense$26M
Balance Sheet Highlights ($ Millions)
Dividend & Shareholder Information
Shares Outstanding24M
Growth Metrics (YoY)
EPS Growth-604.8%
Artiva Biotherapeutics, Inc. (ARTV) Fundamental Analysis & Insider Trading Data
(Quarterly Financial Reports)
Comprehensive quarterly financial data, earnings trends, insider transactions, and institutional holdings for Artiva Biotherapeutics, Inc. stock analysis.
Loading fundamental data...
Loading Artiva Biotherapeutics, Inc. comprehensive fundamental analysis and insider trading data...
Latest Artiva Biotherapeutics, Inc. Stock News & Market Analysis
Breaking news, analyst reports, and market updates affecting Artiva Biotherapeutics, Inc. (ARTV) stock price and investment outlook.
Artiva Biotherapeutics, Inc. (ARTV – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Gil Blum from Needham maintained a Buy rating on the ...
SAN DIEGO, March 31, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell ...
TD Cowen analyst Tyler Van Buren maintained a Buy rating on Artiva Biotherapeutics, Inc. (ARTV – Research Report) yesterday. The company’s shares closed yesterday at $13.07. Van Buren covers ...
SAN DIEGO--(BUSINESS WIRE)--Artiva Biotherapeutics, Inc., a clinical-stage company whose mission is to deliver broadly accessible, off-the-shelf natural killer (NK) cell-based therapies to ...
SAN DIEGO, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell ...
Artiva Biotherapeutics Appoints Edith A. Perez, M.D., to Its Board of Directors and Clinical Advisory Board May 05, 2022 08:00 AM Eastern Daylight Time ...
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV – Get Free Report) has earned a consensus recommendation of “Buy” from the six ratings firms that are covering the company, Marketbeat Ratings reports.
Artiva Biotherapeutics to Participate in the TD Cowen 45th Annual Health Care Conference SAN DIEGO, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage ...
--Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases ...
Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) today announced the pricing of its upsized initial public offering of 13,920,000 shares of common stock at a price to the public of ...
Artiva Biotherapeutics, Inc. Competitors & Peer Analysis - Life Sciences Sector
Comparative analysis of Artiva Biotherapeutics, Inc. against industry peers and competitors in the Life Sciences sector, featuring AI-powered forecasts and key financial metrics.
Frequently Asked Questions - Artiva Biotherapeutics, Inc. Stock Forecast
How accurate are Artiva Biotherapeutics, Inc. stock predictions?
Our AI model demonstrates 69% historical accuracy for ARTV predictions, based on advanced machine learning algorithms trained on over 10 years of market data.
What factors influence Artiva Biotherapeutics, Inc. stock price forecasts?
Is Artiva Biotherapeutics, Inc. a good investment in 2025?
Based on our AI analysis, Artiva Biotherapeutics, Inc. shows potential for various market scenarios. Consider your risk tolerance, investment timeline, and portfolio diversification before making investment decisions.
How often are Artiva Biotherapeutics, Inc. forecasts updated?
Artiva Biotherapeutics, Inc. stock forecasts are updated daily using real-time market data, ensuring you receive the most current AI-powered predictions and investment insights.
Want More Advanced Artiva Biotherapeutics, Inc. Analysis?
Unlock premium features including detailed price targets, risk assessments, portfolio optimization, and real-time alerts for Artiva Biotherapeutics, Inc. stock.
